EQ (Equillium) Payments of Debt: $0.00 Mil (TTM As of Mar. 2026)


EQ Equillium Inc EQ
28 GF Score
Price $2.91
GF Value $0.10
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Equillium Payments of Debt?

Equillium EQ -1.69% 28 Payments of Debt is $0.00 Mil as of Mar. 2026. GuruFocus rates EQ with a GF Score™ of 28/100 and a GF Value™ of $0.10 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Equillium's Payments of Debt for the three months ended in Mar. 2026 was $0.00 Mil.

Equillium's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Equillium Payments of Debt Related Terms

Equillium Payments of Debt Historical Data

* Premium members only.

The historical data trend for Equillium's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Equillium Payments of Debt Chart

Equillium Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only 0.00 -1.43 -9.13 0.00 0.00

Equillium Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
EQ
28GF Score
Equillium Inc EQ
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Equillium Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of $0.00 Mil mean?
Equillium (EQ) has a Payments of Debt of $0.00 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Equillium and its competitors.
Is Equillium's Payments of Debt too high?
Equillium's current Payments of Debt is $0.00 Mil. Overall, Equillium has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Equillium's Payments of Debt compare to ORMP and HUMA?
Equillium's Payments of Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Equillium and its competitors. Equillium's current Payments of Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Equillium stock overvalued right now?
Based on GuruFocus' analysis, Equillium (EQ) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.10, compared to a current price of $2.91 — trading 2810% above its estimated fair value. The current Payments of Debt is $0.00 Mil. Equillium's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Equillium (EQ), the current Payments of Debt is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Equillium (EQ) Overvalued in 2026?

Based on GuruFocus' analysis, Equillium stock appears to be overvalued. The current stock price of $2.91 is trading 2810% above its estimated GF Value™ of $0.10. GuruFocus considers Equillium to be Significantly Overvalued.

Key valuation signals for EQ:

  • Payments of Debt: $0.00 Mil
  • GF Value™: $0.10 vs. price of $2.91 (2810% above fair value)
  • GF Score™: 28/100 with 3 warning signs

No single metric tells the full story. See the EQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Equillium Business Description

Other Exchanges 0A4D:UK0FY:Germany
Address 2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
28GF Score

Get the complete analysis for EQ

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.91
Price
$0.10
GF Value